Cerebrovascular Diseases

Original Paper

Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study

Momosaki R.a · Yasunaga H.b · Kakuda W.a · Matsui H.b · Fushimi K.c · Abo M.a

Author affiliations

aDepartment of Rehabilitation Medicine, The Jikei University School of Medicine, bDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, and cDepartment of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan

Keywords: Early rehabilitationAcute ischemic strokeTissue plasminogen activatorCerebral hemorrhage

Related Articles for ""
Cerebrovasc Dis 2016;42:41-48
https://doi.org/10.1159/000444720

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 04, 2015
Accepted: February 15, 2016
Published online: March 18, 2016
Issue release date: June 2016

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

Background: Although the safety and feasibility of very early rehabilitation for stroke are well recognized, the initiation of rehabilitation is sometimes delayed after thrombolysis. The purpose of this study was to clarify the association between very early rehabilitation and outcomes in acute ischemic stroke patients who received tissue plasminogen activator, using a national inpatient database in Japan. Methods: We identified patients who were admitted to acute-care hospitals with ischemic stroke and were treated with intravenous recombinant tissue plasminogen activator on the same day of stroke onset and received rehabilitation within 3 days from admission. The primary outcome was functional independence on discharge. We compared the outcomes of a very early rehabilitation group with a comparison group. Results: We identified 6,153 eligible patients, of whom 4,266 received very early rehabilitation. The proportion of functional independence on discharge was 41.2 and 36.6% in the very early rehabilitation group and the comparison group, respectively. Multivariable logistic regression analysis showed that the very early rehabilitation was significantly associated with a higher proportion of functional independence after adjustment for confounding factors. There was no significant difference in 7-, 30-, 90-day mortality or incidence of intracerebral hemorrhage between the groups after adjusting for baseline characteristics. Instrumental variable analysis confirmed a higher proportion of functionally independent patients in the very early rehabilitation group. Conclusion: Patients with acute ischemic stroke undergoing very early rehabilitation after thrombolysis were more likely to achieve functional independence without an increase in adverse outcomes.

© 2016 S. Karger AG, Basel

References

  1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
  2. Clark WM, Albers GW, Madden KP, Hamilton S: The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000;31:811-816.
  3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
  4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke 2006;37:1810-1815.
  5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
  6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998;352:1245-1251.
  7. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET Investigators: Effects of alteplase beyond 3 h after stroke in the Echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
  8. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, Peterson ED, Hernandez AF, Fonarow GC, Schwamm LH, Smith EE: Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012;43:2293-2299.
  9. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, Wahlgren N, Ahmed N; SITS Investigators: Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43:1524-1531.
  10. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD; Investigators for the Registry of the Canadian Stroke Network: TPA use for stroke in the registry of the Canadian stroke network. Can J Neurol Sci 2005;32:433-439.
  11. Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, Connolly ES, Mancini B, Prudhomme S, Gress D, Jensen ME, Bass R, Ruff R, Foell K, Armonda RA, Emr M, Warren M, Baranski J, Walker MD; Brain Attack Coalition: Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke 2011;42:2651-2665.
  12. Murphy TH, Corbett D: Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 2009;10:861-872.
  13. Bernhardt J, Dewey H, Thrift A, Collier J, Donnan G: A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke 2008;39:390-396.
  14. Langhorne P, Stott D, Knight A, Bernhardt J, Barer D, Watkins C: Very early rehabilitation or intensive telemetry after stroke: a pilot randomised trial. Cerebrovasc Dis 2010;29:352-360.
  15. Ha J, Churilov L, Linden T, Bernhardt J: Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services. Int J Stroke 2013;8:172-179.
  16. Arnold SM, Dinkins M, Mooney LH, Freeman WD, Rawal B, Heckman MG, Davis OA: Very early mobilization in stroke patients treated with intravenous recombinant tissue plasminogen activator. J Stroke Cerebrovasc Dis 2015;24:1168-1173.
  17. AVERT Trial Collaboration Group, Bernhardt J, Langhorne P, Lindley RI, Thrift AG, Ellery F, Collier J, Churilov L, Moodie M, Dewey H, Donnan G: Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 2015;386:46-55.
  18. Matsuda S, Ishikawa KB, Kuwabara K, Fujimori K, Fushimi K, Hashimoto H: Development and use of the Japanese case-mix system. Eurohealth 2008;14:27-30.
  19. Sulter G, Steen C, De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-1541.
  20. Saposnik G, Webster F, O'Callaghan C, Hachinski V: Optimizing discharge planning: clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke. Stroke 2005;36:147-150.
  21. Ono K, Wada K, Takahara T, Shirotani T: Indications for computed tomography in patients with mild head injury. Neurol Med Chir 2007;47:291-297.
  22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
  23. Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364-375.
  24. Brookhart MA, Rassen JA, Schneeweiss S: Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010;19:537-554.
  25. Matsui H, Hashimoto H, Horiguchi H, Yasunaga H, Matsuda S: An exploration of the association between very early rehabilitation and outcome for the patients with acute ischaemic stroke in Japan: a nationwide retrospective cohort survey. BMC Health Serv Res 2010;10:213.
  26. Staiger D, Stock JH: Instrumental variables regression with weak instruments. Econometrica 1994;65:557-586.
  27. Carmichael ST: Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol 2006;59:735-742.
  28. Biernaskie J, Chernenko G, Corbett D: Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci 2004;24:1245-1254.
  29. Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF: Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair 2012;26:923-931.
  30. Egan KJ, Janssen H, Sena ES, Longley L, Speare S, Howells DW, Spratt NJ, Macleod MR, Mead GE, Bernhardt J: Exercise reduces infarct volume and facilitates neurobehavioral recovery: results from a systematic review and meta-analysis of exercise in experimental models of focal ischemia. Neurorehabil Neural Repair 2014;28:800-812.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 04, 2015
Accepted: February 15, 2016
Published online: March 18, 2016
Issue release date: June 2016

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2016, Vol.42, No. 1-2

June 2016

Article

TAP Icon This Article is Part of
Recommend This
TOP